Cerebral cortical and subcortical cholinergic deficits in parkinsonian syndromes

Objectives: Cholinergic projections to cerebral cortical and subcortical regions are decreased in Parkinson disease (PD), but not evaluated in the parkinsonian syndromes of multiple system atrophy (MSA-P) and progressive supranuclear palsy (PSP). We studied cholinergic innervation in these disorders as compared to age-appropriate normal control subjects. Methods: We used PET with [11C]PMP to measure acetylcholinesterase (AChE) activity in multiple cerebral cortical and subcortical regions. We studied 22 normal controls, 12 patients with PD, 13 patients with MSA-P, and 4 patients with PSP. Results: We found significantly decreased AChE activity in most cerebral cortical regions in PD and MSA-P, and a similar but nonsignificant decrease in PSP. No differences were found between PD and MSA-P. Significantly decreased AChE activity was found in PD in striatum, cerebellum, and thalamus, with a marginally significant decrease in mesencephalon and no change in pons. Significantly greater declines in AChE activity in all subcortical regions were seen in MSA-P and PSP vs in PD. Decreased AChE activity in brainstem and cerebellum of all 3 disorders correlated with disturbances of balance and gait. Conclusions: Cerebral cortical cholinergic activity is decreased to a similar level in Parkinson disease (PD), parkinsonian syndromes of multiple system atrophy (MSA-P), and progressive supranuclear palsy (PSP) as compared to normal controls. Subcortical cholinergic activity is significantly more decreased in MSA-P and PSP than in PD. The more substantial decrease reflects greater impairment in the pontine cholinergic group, which is important in motor activity, particularly gait. These differences may account for the greater gait disturbances in the early stages of MSA-P and PSP than in PD.

[1]  R. Mayeux,et al.  Perceptual motor dysfunction in Parkinson's disease: a deficit in sequential and predictive voluntary movement. , 1983, Journal of neurology, neurosurgery, and psychiatry.

[2]  N. Bohnen,et al.  Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. , 2003, Archives of neurology.

[3]  C D Marsden,et al.  Altered Muscarinic and Nicotinic Receptor Densities in Cortical and Subcortical Brain Regions in Parkinson's Disease , 1993, Journal of neurochemistry.

[4]  S. Mirra,et al.  The nucleus basalis of Meynert in neurological disease: A quantitative morphological study , 1985, Annals of neurology.

[5]  M. Hallett,et al.  Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) , 1996, Neurology.

[6]  Bernard Pillon,et al.  Cognitive deficits in Parkinson’s disease , 1996, Journal of Neurology.

[7]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[8]  P. Davies,et al.  SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE , 1976, The Lancet.

[9]  S. Gilman,et al.  Diagnostic criteria for Parkinson disease. , 1999, Archives of neurology.

[10]  Sid Gilman,et al.  Second consensus statement on the diagnosis of multiple system atrophy , 2008 .

[11]  A. Lees,et al.  Cognitive deficits in the early stages of Parkinson's disease. , 1983, Brain : a journal of neurology.

[12]  Nicola J. Ray,et al.  Anatomy, physiology, and pathophysiology of the pedunculopontine nucleus , 2009, Movement disorders : official journal of the Movement Disorder Society.

[13]  I. Nakano,et al.  Parhnson’s Disease: Neuron Loss in the Nucleus Basah Without Concomitant Alzheimer’s Disease , 2004 .

[14]  E. Perry,et al.  Pathological changes in the nucleus of meynert in Alzheimer's and Parkinson's diseases , 1983, Journal of the Neurological Sciences.

[15]  Jan Voogd,et al.  Chapter 5 Cholinergic innervation and receptors in the cerebellum , 1997 .

[16]  S. Tanada,et al.  PET study of brain acetylcholinesterase in cerebellar degenerative disorders , 2008, Movement disorders : official journal of the Movement Disorder Society.

[17]  V. Bigl,et al.  Loss of neurons in the nucleus basalis of Meynert in Alzheimer's disease, paralysis agitans and Korsakoff's disease , 2004, Acta Neuropathologica.

[18]  C. Bouras,et al.  The basal nucleus of Meynert in idiopathic Parkinson's disease , 1984, Acta neurologica Scandinavica.

[19]  R. Koeppe,et al.  Anatomic standardization: linear scaling and nonlinear warping of functional brain images. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  D. Kuhl,et al.  Synthesis of 1-[11C]methylpiperidin-4-yl propionate ([11C]PMP) for in vivo measurements of acetylcholinesterase activity. , 1998, Nuclear medicine and biology.

[21]  Masanori Ichise,et al.  Widespread decrease of nicotinic acetylcholine receptors in Parkinson's disease , 2006, Annals of neurology.

[22]  E. Sullivan,et al.  Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability. , 1991, Brain : a journal of neurology.

[23]  K. Fukushi,et al.  Design and evaluation of radioactive acetylcholine analogs for mapping brain acetylcholinesterase (AchE) in vivo. , 1994, Nuclear medicine and biology.

[24]  K. Marder,et al.  Neuropsychological characteristics of preclinical dementia in Parkinson's disease , 1995, Neurology.

[25]  D Jaarsma,et al.  Cholinergic innervation and receptors in the cerebellum. , 1997, Progress in brain research.

[26]  M. Mintun,et al.  Automated detection of the intercommissural line for stereotactic localization of functional brain images. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  J. Parisi,et al.  Mesopontine cholinergic neuron involvement in Lewy body dementia and multiple system atrophy , 2008, Neurology.

[28]  D. Kuhl,et al.  In vivo studies of acetylcholinesterase activity using a labeled substrate, N‐[11C]methylpiperdin‐4‐yl propionate ([11C]PMP) , 1996, Synapse.

[29]  S. Minoshima,et al.  In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease , 1996, Annals of neurology.

[30]  David E. Kuhl,et al.  Kinetic Modeling of N-[11C]Methylpiperidin-4-yl Propionate: Alternatives for Analysis of an Irreversible Positron Emission Tomography Tracer for Measurement of Acetylcholinesterase Activity in Human Brain , 1999, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[31]  A. Tröster,et al.  Neuropsychological impairment in Parkinson's disease with and without depression. , 1995, Archives of neurology.

[32]  P. Winn How best to consider the structure and function of the pedunculopontine tegmental nucleus: Evidence from animal studies , 2006, Journal of the Neurological Sciences.

[33]  N. Bohnen,et al.  Cognitive correlates of cortical cholinergic denervation in Parkinson’s disease and parkinsonian dementia , 2006, Journal of Neurology.

[34]  D L Price,et al.  Alzheimer's disease: a disorder of cortical cholinergic innervation. , 1983, Science.

[35]  M. Iyo,et al.  Brain acetylcholinesterase activity: validation of a PET tracer in a rat model of Alzheimer's disease. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[36]  C. Marsden,et al.  'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa. , 1988, Brain : a journal of neurology.

[37]  S Tanada,et al.  Positron emission tomographic measurement of acetylcholinesterase activity reveals differential loss of ascending cholinergic systems in Parkinson's disease and progressive supranuclear palsy , 1999, Annals of neurology.

[38]  D L Price,et al.  Basal forebrain neurons in the dementia of Parkinson disease , 1983, Annals of neurology.

[39]  D E Kuhl,et al.  Quantification of Muscarinic Cholinergic Receptors with [11C]NMPB and Positron Emission Tomography: Method Development and Differentiation of Tracer Delivery from Receptor Binding , 1998, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[40]  S. Minoshima,et al.  In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer’s disease , 1999, Neurology.

[41]  M W Mahowald,et al.  Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. , 2007, Brain : a journal of neurology.